Phase II
Ongoing proof-of-concept trial AdrenOSS-II testing Adrecizumab in early septic shock
Thomas Wicks, chief strategy officer of New Jersey-based TrialScope, said transparency has picked up over the past few years, particularly as large pharma companies have begun to release information about their own clinical efforts.
Shares of Solid Biosciences have plunged more than 71 percent after the company revealed early data from a Phase I/II trial that showed low doses of its gene therapy treatment may lack the potential to be as effective a treatment for Duchenne muscular dystrophy as current products on the market.
Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatment
Across the globe, pharma companies are making an impact. Last week BioSpace launched the first of a weekly roundup of international biotech and pharma news. Here’s the latest edition.
Roche announced that it was discontinuing two of its Alzheimer’s Phase III trials, CREAD I and 2, after a pre-planned interim analysis.
Karolinska Development’s portfolio company Umecrine Cognition announces overall results from a phase 2a study with the candidate drug GR3027 in patients with idiopathic hypersomnia.
Under terms of the agreement, Neurocrine provided Voyager with $165 million in an upfront payment, along with funding for ongoing development of each program. If developmental, regulatory and commercial milestones are hit, Voyager could snag up to $1.7 billion.
Real-world evidence (RWE) or real-world data (RWD) relates to the collection of information about a drug’s safety and efficacy outside the structure of a clinical trial. Speaking yesterday, FDA Commissioner Scott Gottlieb laid out the FDA’s new framework for dealing with RWE and RWD.
Evotec’s partner, second genome, begins a phase ii clinical trial for nash with licensed molecule, sgm-1019
PRESS RELEASES